Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia
详细信息 查看全文
- 作者：Jonathan Kell Jonathan.Kell@wales.nhs.uk" class="auth_mail" title="E-mail the corresponding author
- 关键词：Acute myeloid leukemia ; Relapse ; Refractory
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：47
- 期：Complete
- 页码：149-160
- 全文大小：1231 K
文摘
- •
Relapsed and refractory AML remains an area of unmet clinical need.
- •
Cytogenetics and duration of first CR remain the most important prognostic factors.
- •
Treatment decisions should be based on patient characteristics and performance status.
- •
Intensive chemotherapy can induce second remission in up to 76% of younger adults.
- •
Novel agents need further randomised studies to confirm clinical benefit.